To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

Exclusion Criteria

• •1. Females who are pregnant, breast feeding, or planning a pregnancy.
• •2. Females of childbearing potential who do not agree to utilize an adequate form of contraception
• •3. Current, or past history of, severe hepatic or renal impairment
• •4. Current, or history within two months prior to baseline of, significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye
• •5. Current corneal abnormalities that would prevent accurate readings with the Goldmann applanation tonometer
• •6. Functionally significant visual field loss
• •7. Contraindication to brinzolamide or sulfonamide therapy or known hypersensitivity to any component of brinzolamide or sulfonamide therapy
• •8. Use at any time prior to baseline of an intraocular corticosteroid implant
• •9. Use within one week prior to baseline of contact lens
• •10. Use within two weeks prior to baseline of: 1) topical ophthalmic corticosteroid, or 2) topical corticosteroid
• •11. Use within one month prior to baseline of: 1) systemic corticosteroid or 2) high-dose salicylate therapy
• •12. Use within six months prior to baseline of intravitreal or subtenon injection of ophthalmic corticosteroid
• •13. Having undergone within six months prior to baseline any other intraocular surgery (e.g., cataract surgery)
• •14. Having undergone within twelve months prior to baseline refractive surgery, filtering surgery, or laser surgery for pressure reduction